Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2

Tiffany Mayo,Susan Taylor,Taisuke Ito, Sergio Vano Galvan,Susan G. Ball,Na Lu,Chiara Chiasserinio,Yun-Fei Chen,Brittany Craiglow

AUSTRALASIAN JOURNAL OF DERMATOLOGY（2023）

引用 1|浏览15

暂无评分

摘要

Introduction: Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss. Baricitinib, an oral, JAK1/ JAK2 inhibitor has been approved for treatment of adults with severe AA in the US, Europe, and Japan.

查看译文

关键词

alopecia areata,efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要